BioVersys AG (FRA:W33) Total Current Assets: €96.31 Mil (As of Dec. 2025)


FRA:W33 BioVersys AG FRA:W33
7 GF Score
Price €28.40
View Full Analysis

What is BioVersys AG Total Current Assets?

BioVersys AG FRA:W33 +1.43% 7 Total Current Assets is €96.31 Mil as of Dec. 2025. GuruFocus rates FRA:W33 with a GF Score™ of 7/100.

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. BioVersys AG's total current assets for the quarter that ended in Dec. 2025 was €96.31 Mil.

BioVersys AG  (FRA:W33) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

BioVersys AG's Liquidation Value for the quarter that ended in Dec. 2025 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=88.417-33.034+0.75 * 0+0.5 * 0
=55.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioVersys AG Total Current Assets Related Terms

BioVersys AG Total Current Assets Historical Data

* Premium members only.

The historical data trend for BioVersys AG's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioVersys AG Total Current Assets Chart

BioVersys AG Annual Data
Trend Dec24 Dec25
Total Current Assets
36.84 96.31

BioVersys AG Semi-Annual Data
Jun24 Dec24 Jun25 Dec25
Total Current Assets 0.00 36.84 100.52 96.31
FRA:W33
7GF Score
BioVersys AG FRA:W33
Total Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioVersys AG Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

BioVersys AG's Total Current Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=88.417+0.969+0+6.924
=96.31

BioVersys AG's Total Current Assets for the quarter that ended in Dec. 2025 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=88.417+0.969+0+6.924
=96.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Frequently Asked Questions Learn more about Total Current Assets →
What does a Total Current Assets of €96.31 Mil mean?
BioVersys AG (FRA:W33) has a Total Current Assets of €96.31 Mil as of Dec. 2025. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for BioVersys AG and its competitors.
Is BioVersys AG's Total Current Assets too high?
BioVersys AG's current Total Current Assets is €96.31 Mil. Overall, BioVersys AG has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does BioVersys AG's Total Current Assets compare to VRTX and REGN?
BioVersys AG's Total Current Assets of €96.31 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Assets for a Biotechnology company?
A good Total Current Assets depends on the Biotechnology industry context. However, Total Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Assets mean?
A high Total Current Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for BioVersys AG and its competitors. BioVersys AG's current Total Current Assets is €96.31 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVersys AG stock overvalued right now?
BioVersys AG (FRA:W33) has a current Total Current Assets of €96.31 Mil. The current Total Current Assets is €96.31 Mil. BioVersys AG's overall GF Score™ is 7/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Assets calculated?
Total Current Assets is calculated from a company's financial statements. For BioVersys AG (FRA:W33), the current Total Current Assets is €96.31 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioVersys AG Business Description

Other Exchanges BIOVz:UKBIOV:Switzerland
Address c/o Technologiepark, Hochbergerstrasse 60c, Basel, CHE, CH-4057
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
7GF Score

Get the complete analysis for FRA:W33

Total Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€28.40
Price